Esreboxetine - Axsome Therapeutics
Alternative Names: [S,S]-Reboxetine; AXS-14; PNU-165442GLatest Information Update: 09 Aug 2024
At a glance
- Originator Pfizer
- Developer Axsome Therapeutics; Pfizer
- Class Antidepressants; Morpholines; Small molecules; Urologics
- Mechanism of Action Adrenergic uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Fibromyalgia
- Discontinued Diabetic neuropathies; Major depressive disorder; Postherpetic neuralgia; Stress incontinence
Most Recent Events
- 05 Aug 2024 Axsome Therapeutics announces intention to submit NDA to the US FDA for Fibromyalgia in the third quarter of 2024
- 27 Sep 2022 Esreboxetine is still in phase III clinical trials in Fibromyalgia in USA (PO) (Axsome Therapeutics website, September 2022)
- 10 May 2021 Axsome Therapeutics met the US FDA for clinical development of esreboxetine for fibromyalgia, before May 2021